|
Supplements Lead to More Burdens Than Standard Filings, Tufts Finds
NDA and BLA supplements have created more headaches for pharma companies than standard new drug or biologic applications, finds a new study from the Tufts Center for the Study of Drug Development.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives